Engineered immune cells take on deadly brain cancer in early trial
NCT ID NCT05353530
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 23 times
Summary
This early-phase study tests a personalized cell therapy for adults with glioblastoma and children with high-grade gliomas. The treatment uses a patient's own immune cells, modified to target a protein called CD70 on tumor cells and to better navigate to the brain. The main goals are to see if the therapy is safe and feasible to deliver.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Florida Health
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.